Who is sponsoring NCT05399732?

NCT05399732 is sponsored by Bing Han.

What condition does NCT05399732 study?

NCT05399732 studies Aplastic Anemia.

What drugs are being tested in NCT05399732?

Interventions: Luspatercept, Cyclosporine.

What is the status of NCT05399732?

NCT05399732 is currently COMPLETED.

Last reviewed 2025-09-16 · How we verify

Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia

NCT05399732 PHASE2 COMPLETED

Aplastic anemia (AA) is a rare bone marrow failure disease characterized by bone marrow hypocellularity and peripheral blood pancytopenia. AA is divided into severe AA (SAA) and non-severe AA (NSAA) based on the degree of cytopenia. The first line therapy for SAA or transfusion dependent NSAA is either immunosuppression therapy (IST) or hematopoietic stem cell transplantation (HSCT). Little attention has been paid to patients with anemia but not transfusion dependent, whose quality of life is significantly impaired due to the anemia and other complications.

Details

Lead sponsor	Bing Han
Phase	PHASE2
Status	COMPLETED
Enrolment	58
Start date	Mon Dec 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Aplastic Anemia

Interventions

Luspatercept
Cyclosporine

Countries

China